Sign up
Pharma Capital

Horizon Discovery Group bids farewell to Abcam founder who exits board following failed bid approach

Jonathan Milner's exit ends a decade-long association with Horizon and he wished the team there well, adding he felt "enormously privileged to have been a part of this exciting journey"
boardroom table
Will Horizon look to fill the vacant non-executive director position or leave the seat vacant

It was all very cordial, but there was an air of inevitability about the departure of Dr Jonathan Milner from the board of gene editing specialist Horizon Discovery Group PLC (LON:HZD).

For those unaware of the background, Abcam PLC (LON:ABC), the company founded by Milner, recently launched an unwelcome £270mln bid for Horizon that ultimately failed.

Milner's exit ends a decade-long association with Horizon and he wished the team there well, adding he felt "enormously privileged to have been a part of this exciting journey"

Enthusiastic about the future 

"I continue to be encouraged and enthusiastic about the growth prospects of Horizon's business, and intend to remain a shareholder for the foreseeable future," he went on.

Horizon chairman Dr Ian Gilham for his part said he was sorry to see Milner depart, but understood the decision to prioritise "other commitments"

"We are extremely grateful for his valuable insights as a member of Horizon's board over many years and wish him well in his future, not least as a considerable founding shareholder of the Horizon business."



Register here to be notified of future HZD Company articles
View full HZD profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.